FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> swine flu | Vaccine | Novavax

Novavax shares spike on new vaccine success

Tools
  • Email
  • Print
  • Comment
  • Contact Author
  • Reprint

Shares of Novavax spiked 21 percent after the company announced that it was able to create a swine flu vaccine with its virus-like particle technology in only 11 weeks.

"Demonstration of our ability to construct and produce GMP-quality influenza vaccine within 12 weeks under real pandemic conditions is an important and successful test of our VLP technology," Jim Robinson, vice president of manufacturing and quality operations at Novavax, said in a statement. VLP technology uses an artificial virus that doesn't contain the genetic material required for transmission.

Novavax has completed a Phase I/IIa clinical study with a candidate H5N1 influenza VLP vaccine and is currently in Phase II trials with a VLP based seasonal flu vaccine candidate. The company plans to initiate a Phase II study with its seasonal flu vaccine candidate in the elderly population during Q4.

- read the story from Reuters

Related Articles:
Deals help Novavax pay off $22M in debts
Novavax shares skyrocket on European vax pact
Novavax shares soar on NIH swine flu agreement
Novavax gets $11M, forges Indian joint venture

More stories about swine flu   Vaccine   Novavax  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.